Trimethoprim

證據等級: L5

預測適應症: 2 個

Trimethoprim: From Systemic Antibacterial Therapy to Bacterial Conjunctivitis

One-Sentence Summary

Trimethoprim is a DHFR-inhibiting antibacterial agent conventionally used for systemic and topical bacterial infections. The TxGNN model’s #2-ranked prediction identifies Conjunctivitis as a target indication, supported by 3 clinical trials (including one direct head-to-head RCT) and 20 publications. Note: TxGNN’s #1-ranked prediction — punctate epithelial keratoconjunctivitis (score 99.57%) — currently has zero supporting evidence (L5/Hold) and a mechanistically weak rationale (the condition is largely viral/immune-mediated, not bacterial), so it is not the focus of this report.

Quick Overview

Item	Content
Original Indication	Not on file (0 US licenses; product currently “未上市”/Not Marketed in this registry)
Predicted New Indication	Conjunctivitis (bacterial)
TxGNN Prediction Score	99.17%
Evidence Level	L1
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the structured drug registry (flagged as a High-severity data gap). Based on the repurposing rationale accompanying this evidence pack, Trimethoprim inhibits bacterial dihydrofolate reductase (DHFR), blocking the folate synthesis pathway required for bacterial DNA synthesis. This antibacterial mechanism has well-established efficacy against Gram-positive and Gram-negative pathogens.

Bacterial conjunctivitis is caused by common ocular pathogens (Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus) that are susceptible to trimethoprim’s antifolate mechanism. This is not a purely computational hypothesis: trimethoprim combined with polymyxin B (marketed as Polytrim) is already an FDA-approved, clinically established topical treatment for bacterial conjunctivitis in the US, which strongly corroborates the TxGNN prediction with real-world precedent.

By contrast, the model’s top-ranked candidate (punctate epithelial keratoconjunctivitis) lacks this mechanistic coherence — that condition is predominantly viral (e.g., adenoviral) or immune-mediated, so an antibacterial agent’s applicability is speculative and currently unsupported by any trial or literature evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00581542	Phase 4	Completed	124	Single-blind RCT directly comparing Polytrim (trimethoprim/polymyxin B) ophthalmic solution vs. moxifloxacin for treating pediatric conjunctivitis; direct efficacy comparison (Grade A relevance).
NCT03187834	Phase 4	Completed	252	Population-level study of antibiotic resistance and microbiome changes in children after short-course antibiotic use; indirect safety/resistance evidence (Grade B).
NCT00168532	Phase 3	Completed	218	Community-based double-blind placebo-controlled RCT of prophylactic antibiotics in measles (conjunctivitis is a common measles complication, but not the primary endpoint) (Grade B).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19043945	2008	RCT	J Pediatr Ophthalmol Strabismus	Multicenter comparison of polymyxin B/trimethoprim vs. 0.5% moxifloxacin on speed of clinical efficacy in bacterial conjunctivitis.
6204534	1984	RCT	Am J Ophthalmol	Clinical evaluation of trimethoprim-containing ophthalmic solutions (with sulfacetamide or polymyxin B) in bacterial conjunctivitis/blepharitis.
30007329	2018	Review (systematic review/meta-analysis)	J Pediatr Infect Dis Soc	Systematic review of antibiotic treatments, including trimethoprim, for neonatal chlamydial conjunctivitis.
8595639	1995	Cohort	Clin Ther	Survey of children with acute bacterial conjunctivitis treated with trimethoprim-polymyxin B ophthalmic solution.
21988450	2011	Clinical study	Curr Eye Res	Analysis of nontypeable Streptococcus pneumoniae in sporadic bacterial conjunctivitis cases (context for antibacterial targeting).
16491721	2006	Review	J Pediatr Ophthalmol Strabismus	Guidance on controlling contagious bacterial conjunctivitis outbreaks with antimicrobial therapy.
20084257	2001	Review	Paediatr Child Health	Review of etiology, clinical features, and management of acute infectious conjunctivitis in children.
34943657	2021	Clinical study	Antibiotics (Basel)	Clinical/molecular characteristics of MSSA ocular infections in Taiwan, relevant to bacterial ocular pathogen susceptibility.

US Market Information

Currently not marketed under this registry — 0 NDA licenses on file (market_status: 未上市 / Not Marketed). No product/authorization data available to tabulate.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are not currently available in this evidence pack; TFDA/FDA label review is a Blocking data gap for safety screening.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The conjunctivitis indication is backed by L1-level evidence, including a Grade A completed Phase 4 RCT (NCT00581542) directly comparing trimethoprim/polymyxin B to moxifloxacin, plus an existing FDA-approved precedent (Polytrim). This is a mechanistically coherent, clinically corroborated repurposing candidate — not a speculative model output.

To proceed, the following is needed:

TFDA/FDA package insert data (warnings, contraindications) — currently a Blocking data gap (DG001)
Formal drug interaction (DDI) data — currently not_found
Confirmation of route compatibility (ophthalmic formulation availability/status is marked “pending”)
Deprioritize or separately re-evaluate the higher-scored but evidence-free candidate (punctate epithelial keratoconjunctivitis, L5/Hold) before any further investment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.